These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

139 related articles for article (PubMed ID: 26675224)

  • 1. Development and approval of novel injectables: enhancing therapeutic innovations.
    Yadav P; Singh Y; Chauhan D; Yadav PK; Kedar AS; Tiwari AK; Shah AA; Gayen JR; Chourasia MK
    Expert Opin Drug Deliv; 2024 Apr; 21(4):639-662. PubMed ID: 38703363
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Pharmacokinetics of inhaled nanotherapeutics for pulmonary delivery.
    Shen AM; Minko T
    J Control Release; 2020 Oct; 326():222-244. PubMed ID: 32681948
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Harnessing inhaled nanoparticles to overcome the pulmonary barrier for respiratory disease therapy.
    Jin Z; Gao Q; Wu K; Ouyang J; Guo W; Liang XJ
    Adv Drug Deliv Rev; 2023 Nov; 202():115111. PubMed ID: 37820982
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Strategies for overcoming the biological barriers associated with the administration of inhaled monoclonal antibodies for lung diseases.
    Matera MG; Calzetta L; Rinaldi B; Cazzola M; Rogliani P
    Expert Opin Drug Deliv; 2023; 20(8):1085-1095. PubMed ID: 37715502
    [TBL] [Abstract][Full Text] [Related]  

  • 5. An evolving perspective on novel modified release drug delivery systems for inhalational therapy.
    Hye T; Moinuddin SM; Sarkar T; Nguyen T; Saha D; Ahsan F
    Expert Opin Drug Deliv; 2023 Mar; 20(3):335-348. PubMed ID: 36720629
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Recent Updates in Inhalable Drug Delivery System against Various Pulmonary Diseases: Challenges and Future Perspectives.
    Chaudhary KR; Singh K; Singh C
    Curr Drug Deliv; 2024; 21(10):1320-1345. PubMed ID: 37870055
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Liposomes for Inhalation.
    Ong HX; Traini D; Young PM
    J Aerosol Med Pulm Drug Deliv; 2024 Apr; 37(2):100-110. PubMed ID: 38640446
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Particulate bioaerogels for respiratory drug delivery.
    Li HY; Makatsoris C; Forbes B
    J Control Release; 2024 Jun; 370():195-209. PubMed ID: 38641021
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Imaging drug delivery to the lungs: Methods and applications in oncology.
    Man F; Tang J; Swedrowska M; Forbes B; T M de Rosales R
    Adv Drug Deliv Rev; 2023 Jan; 192():114641. PubMed ID: 36509173
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Targeted Molecular Therapeutics for Pulmonary Diseases: Addressing the Need for Precise Drug Delivery.
    Carneiro S; Müller JT; Merkel OM
    Handb Exp Pharmacol; 2024; 284():313-328. PubMed ID: 38177399
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Overview of processed excipients in ocular drug delivery: Opportunities so far and bottlenecks.
    Ashique S; Mishra N; Mohanto S; Gowda BHJ; Kumar S; Raikar AS; Masand P; Garg A; Goswami P; Kahwa I
    Heliyon; 2024 Jan; 10(1):e23810. PubMed ID: 38226207
    [TBL] [Abstract][Full Text] [Related]  

  • 12. "Inactive" ingredients in oral medications.
    Reker D; Blum SM; Steiger C; Anger KE; Sommer JM; Fanikos J; Traverso G
    Sci Transl Med; 2019 Mar; 11(483):. PubMed ID: 30867323
    [TBL] [Abstract][Full Text] [Related]  

  • 13. MAbDelivery: Administration routes for antibody therapy Third LabEx MAbImprove industrial workshop, July 2, 2015 Tours, France.
    Bodier-Montagutelli E; Respaud R; Watier H; Guillon-Munos A
    MAbs; 2017; 9(4):579-585. PubMed ID: 28346048
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Inhaled Lipid Nanoparticles: A Feasible Tool for a Challenging Route.
    Leo E; Maretti E
    Curr Drug Deliv; 2024; 21(3):309-311. PubMed ID: 36762750
    [No Abstract]   [Full Text] [Related]  

  • 15. Ion-dependent slow protein release from
    Álamo P; Parladé E; López-Laguna H; Voltà-Durán E; Unzueta U; Vazquez E; Mangues R; Villaverde A
    Drug Deliv; 2021 Dec; 28(1):2383-2391. PubMed ID: 34747685
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Breakthroughs in modern cancer therapy and elusive cardiotoxicity: Critical research-practice gaps, challenges, and insights.
    Zheng PP; Li J; Kros JM
    Med Res Rev; 2018 Jan; 38(1):325-376. PubMed ID: 28862319
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Innovative formulations for controlled drug delivery to the lungs and the technical and toxicological challenges to overcome(.).
    Aragao-Santiago L; Bohr A; Delaval M; Dalla-Bona AC; Gessler T; Seeger W; Beck-Broichsitter M
    Curr Pharm Des; 2016; 22(9):1147-60. PubMed ID: 26675224
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Formulation strategy and use of excipients in pulmonary drug delivery.
    Pilcer G; Amighi K
    Int J Pharm; 2010 Jun; 392(1-2):1-19. PubMed ID: 20223286
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Cyclodextrin-Based Formulations: A Non-Invasive Platform for Targeted Drug Delivery.
    Muankaew C; Loftsson T
    Basic Clin Pharmacol Toxicol; 2018 Jan; 122(1):46-55. PubMed ID: 29024354
    [TBL] [Abstract][Full Text] [Related]  

  • 20.
    ; ; . PubMed ID:
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 7.